Ecallantide is a novel treatment for attacks of hereditary angioedema due to C1 inhibitor deficiency
Open Access
- 1 May 2011
- journal article
- review article
- Published by Informa UK Limited in Clinical, Cosmetic and Investigational Dermatology
- Vol. 4, 61-68
- https://doi.org/10.2147/ccid.s10322
Abstract
Abstract: Hereditary angioedema (HAE) resulting from the deficiency of the C1 inhibitor protein is a rare disease, characterized by paroxysms of edema formation in the subcutis and in the submucosa. Edema can cause obstruction of the upper airway, which may lead to suffocation. Prompt elimination of edema is necessary to save patients from this life-threatening condition. Essentially, these edematous attacks are related to the activation of the kinin-kallikrein system and the consequent release of bradykinin. Ecallantide (known as DX-88 previously), a potent and specific inhibitor of plasma kallikrein is an innovative medicinal product. This is the only agent approved recently by the FDA for all localizations of edematous HAE attacks. Its advantages include no risk of viral contamination, high selectivity, very rapid onset of action, good tolerability, and straightforward subcutaneous administration. Owing to the risk of anaphylaxis, ecallantide should be administered by a health care professional. A postmarketing survey to improve risk-assessment and risk-minimization has been launched. The results of these studies may lead to the approval of ecallantide for self-administration.Keywords
This publication has 47 references indexed in Scilit:
- 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedemaAllergy, Asthma & Clinical Immunology, 2010
- HAE therapies: past present and futureAllergy, Asthma & Clinical Immunology, 2010
- HAE international home therapy consensus documentAllergy, Asthma & Clinical Immunology, 2010
- Management of upper airway edema caused by hereditary angioedemaAllergy, Asthma & Clinical Immunology, 2010
- Prospective Study of Rapid Relief Provided by C1 Esterase Inhibitor in Emergency Treatment of Acute Laryngeal Attacks in Hereditary AngioedemaJournal of Clinical Immunology, 2010
- EcallantideDrugs, 2010
- Economic costs associated with acute attacks and long-term management of hereditary angioedemaAnnals of Allergy, Asthma & Immunology, 2010
- Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patientsAnnals of Allergy, Asthma & Immunology, 2008
- Hereditary angiodema: a current state-of-the-art review, IV: short- and long-term treatment of hereditary angioedema: out with the old and in with the new?Annals of Allergy, Asthma & Immunology, 2008
- AngioedemaJournal of the American Academy of Dermatology, 2005